Review Article
Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
Table 2
Summary of data in the metastatic setting.
| | Author (year) | Line of treatment
Type of trial | Drug(s) | Number of patients evaluable for end points | Results |
| | Yoshimoto et al. [11] | 1st-2nd line
Phase II | CAPE 828 mg/m2 twice daily + CTX 33 mg/m2 twice daily, dd 1 → 14, every 21 days | 9 | ORR 44.4%
CBR 57.8%
Median PFS 10.7 months |
| | Wang et al. [12] | 2nd line or further
(maintenance)
Phase II | CTX 50 mg daily (after CTX 3 g/m2 for the preparation of CD34+ and CTX 3 g/m2, thiotepa 150 mg/m2, and CBDCA AUC = 6, every 28 dd for 2 courses) | 23 | NA |
| | Kummar et al. [13] | 2nd line or further
Phase II | CTX 50 mg/day
versus
CTX 50 mg/day + Veliparib 60 mg once daily throughout a 21-day cycle | 39 | ORR 5.6% versus 9.5%
(NS) |
|
|
ORR = overall response rate; CBR = clinical benefit rate; PFS = progression-free survival; CBDCA = carboplatin.
|
